Patent: 10,478,478

Summary for Patent: 10,478,478

Title:	Treatment of Raynaud\'s phenomenon using botulinum toxin type B
Abstract:	An effective amount of botulinum toxin type B is administered to a subject in need thereof for treating Raynaud\'s phenomenon. Botulinum toxin type B may be in a form of an injection, and may be locally administered to a disease affected site, in a dose of 200 to 400 units per disease affected site.
Inventor(s):	Motegi; Sei-ichiro (Gunma, JP)
Assignee:	NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (Gunma, JP)
Application Number:	15/941,089
Patent Claims:	see list of patent claims

United States Patent 10,478,478: Claims, Validity Pressure Points, and US Landscape for Botulinum Toxin Type B Injection in Raynaud’s Phenomenon

What does US 10,478,478 claim, and where is it narrow?

US 10,478,478 claims a specific clinical method for treating Raynaud’s phenomenon using botulinum toxin type B delivered by a defined injection pattern in the hand.

Independent claim 1 (core method)

Claim 1 requires all elements below (the injection site definition is central):

• Therapeutically effective amount of botulinum toxin type B
• Injected into sites between fingers
• Injected also at the external sides of metacarpophalangeal (MCP) joints of the first and fifth fingers (thumb-side and little-finger side)

The claim does not broadly cover any botulinum toxin use in Raynaud’s. It ties the treatment to a hand-specific anatomical injection map using type B toxin.

Dependent claim 2 (dose constraint)

Claim 2 adds a numeric dosing limitation:

• 200 to 400 units per injection

Because it is dependent, claim 2 narrows claim 1 by constraining dose per injection event.

How defensible are these claims against prior art?

The defensibility hinges on two claim anchors: (1) toxin identity (type B) and (2) injection-site geometry.

The risk profile: type B vs type A

Raynaud’s treatment with botulinum toxins is an established theme. The key validity question is whether prior art already taught:

1. Using botulinum toxin type B (not type A) for Raynaud’s, and/or
2. Injecting into the hand in a particular distribution tied to finger web spaces and lateral MCP sides.

If prior art taught Raynaud’s treatment using botulinum toxin (especially type A) without teaching type B or the specific injection map, then claim 1’s injection pattern and type B identity may still carve out novelty.

If prior art taught type B specifically for Raynaud’s, then claim 1 faces direct anticipation risk unless the injection placement is demonstrably different.

The risk profile: injection map specificity

The injection-site limitation is unusually specific for a method-of-treatment claim. That specificity can cut both ways:

• Pro-defense: It distinguishes from more generic teachings (for example, “inject into the hands,” “inject into the digits,” or “inject along sympathetic pathways”).
• Pro-attack: If prior art already disclosed essentially the same anatomical sites (finger web spaces and lateral MCP sides of thumb and little finger), claim 1 can be attacked as anticipated or obvious.

The claim’s language also creates a mapping requirement:

• “between fingers” plus
• “external sides of metacarpophalangeal joints of the first and fifth fingers”

That wording invites a close comparison to earlier injection schemes. Even small differences in described locations can matter for anticipation, but for obviousness, an obvious substitution argument may still be made if prior art provides an injection rationale.

What would an examiner or challenger likely target?

Without the specification text or prosecution history, the challenge strategy for US 10,478,478 typically clusters into four bins: anticipation, obviousness, indefiniteness, and written description.

1) Anticipation: prior art that matches both toxin type and placement

A strong anticipation attack needs a single reference that discloses:

• Botulinum toxin type B
• Used to treat Raynaud’s phenomenon
• With injection into between fingers and external sides of MCP joints at first and fifth fingers

If such a reference exists, claim 1 collapses.

2) Obviousness: combination of type B teaching and hand injection guidance

Even if no single reference discloses the full combination, claim 1 may still be obvious if prior art provides:

• A teaching that botulinum toxin (type B or switchable between types) treats Raynaud’s, and
• Separate evidence that the same hand injection sites are effective for vascular spasm conditions or digit ischemia

Since claim 1 does not limit patient phenotype, severity, or contraindications, a challenger can argue broad applicability.

3) Claim construction pressure: “between fingers” and “external sides”

Terms like “between fingers” and “external sides of MCP joints” can generate construction disputes:

• Are injection points in the web space only, or along volar/dorsal margins?
• Is “external side” radial side of thumb and ulnar side of fifth MCP only, or does it include adjacent borders?

If a prior art method used the same functional goal but different anatomical phrasing, a challenger may argue obviousness by equivalence.

4) Dependent claim 2: 200 to 400 units per injection

This dose range can be attacked if:

• Prior art uses overlapping dosing (within 200 to 400 units) for similar hand injections, or
• Prior art teaches a broader dosing range that includes 200-400 units such that selecting that sub-range is routine

Conversely, if dose selection is tied in the specification to the injection map and outcomes, the dose range can still help narrow obviousness.

Where does the landscape likely sit (US-focused) given the claim content?

US 10,478,478 is anchored to a method using botulinum toxin type B with a defined finger/MCP injection pattern. That makes it more similar to “anatomical injection protocol” families than to broad “botulinum toxin for vascular spasm” method-of-treatment filings.

Landscape segmentation

For investment and R&D positioning, the relevant US universe typically splits into:

• Botulinum toxin for Raynaud’s (method claims)
• Botulinum toxin type B specifically (substance-specific claims)
• Digit/hand injection patterns (anatomical delivery claims)
• Dose-ranging claims (unit constraints)

A claim like 10,478,478 will be strongest if the field has only type A Raynaud’s work or only generic hand injections. It will be weakest if the field already mapped similar web-space and lateral MCP injection points using type B.

Practical claim strength scorecard (what matters to enforcement)

The enforcement power depends on what competing products and clinicians actually do.

Literal infringement sensitivity

Claim 1 requires:

• Type B (not type A or type F)
• Injection at the specified locations
• Treatment of Raynaud’s phenomenon

So infringement exposure is highest when:

• A clinician or label-directed protocol follows the thumb and little finger lateral MCP plus between-finger web injections.

It drops when:

• The injection map is different (for example, purely palmar digit injections, symmetric finger web injections without MCP-lateral targeting, or pathway injections)
• The toxin is type A

Design-around pathways

Competitors can reduce risk by:

• Switching from type B to type A (if clinically effective)
• Using a materially different injection map that targets different anatomical landmarks
• Avoiding the 200-400 units per injection dosing window (for claim 2)

Even if a product still treats Raynaud’s with type B, it may fall outside claim 1 if injection placement does not meet the defined sites.

Competitive intelligence: how to read other patents and clinical protocols against US 10,478,478

When assessing the patent landscape, focus on documents that match at least three of the four elements: (i) Raynaud’s indication, (ii) botulinum toxin type, (iii) hand/digit injection anatomy, (iv) dosing protocol.

Most relevant prior-art patterns to search

• “Raynaud” + “botulinum toxin type B”
• “Raynaud” + “digit” + “web space” + “MCP”
• “botulinum toxin” + “sympathetic” + “hand” + “Raynaud”
• Protocol papers or patent claims specifying finger-level injection coordinates

Why “MCP lateral sides” are key

Many injection protocols describe digit involvement at a general level (for example, along the symptomatic fingers). “External sides of MCP joints” of first and fifth fingers creates a unique geometry. That is where novelty and non-obviousness can live if the field’s earlier work does not specify those landmarks.

Key takeaways

• US 10,478,478 is not a broad botulinum-toxin-for-Raynaud claim. It is a protocol claim requiring type B and a specific injection map: between-finger sites and lateral MCP sides of the first and fifth fingers.
• Dependent claim 2 narrows dosing to 200 to 400 units per injection, which can reduce obviousness risk if prior art dose ranges do not overlap tightly and if clinical support ties that range to the method.
• Validity pressure points concentrate on injection-site disclosure and type B specificity. If prior art already used type B for Raynaud’s with closely matching anatomy, claim 1 faces high anticipation/obviousness risk.
• Enforcement is injection-map sensitive. A design-around that changes toxin type or uses a different hand/digit target anatomy can substantially weaken infringement risk.
• Landscape review should prioritize documents that specify Raynaud’s + botulinum type B + digit/hand injection coordinates, especially those referencing finger web spaces and MCP-lateral placement.

FAQs

1) Is claim 1 a broad treatment method for Raynaud’s with botulinum toxin type B?

No. It is restricted by both toxin type (type B) and specific hand injection locations: between fingers and the external sides of MCP joints of the first and fifth fingers.

2) What does claim 2 add relative to claim 1?

Claim 2 adds a numeric dosing limit: 200 to 400 units per one injection.

3) What is the most likely validity challenge against claim 1?

A challenge that finds prior art disclosing botulinum toxin type B for Raynaud’s along with an injection placement scheme that matches the claimed between-finger and lateral MCP sites for the first and fifth fingers.

4) How can competitors design around this patent most effectively?

By changing at least one essential element: use a different toxin type (type A instead of type B), and/or adopt an injection anatomy that does not target the claimed between-finger sites and external MCP sides of the first and fifth fingers; also avoid the 200-400 units per injection dosing if targeting claim 2.

5) Does the claim scope depend on patient subgrouping (severity, primary vs secondary Raynaud’s)?

No subgroup elements appear in the provided claim text; the method is defined broadly for “a subject in need thereof” suffering from Raynaud’s phenomenon.

---

References

[1] United States Patent 10,478,478. Claims provided in user prompt.

Details for Patent 10,478,478

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	December 08, 2000	10,478,478	2038-03-30